Effects of Remimazolam on Quality of Recovery After Ambulatory Surgery

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

38 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-11-01

Study Completion Date

2021-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Remimazolam is a novel ultra-short acting benzodiazepine with rapid onset of effects, short maintenance and faster recovery time. Due to its recent development, few studies have investigated the effect of remimazolam on postoperative recovery mainly focusing on physiologic endpoints, recovery time and possible adverse events. Although these parameters are crucial and need evaluation, the investigators ignore quality of recovery from participant's perspective. For this purpose, various measurment tools have been developed for psychometric evaluation of QoR score.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Reversal of Remimazolam by a Single Dose of Flumazenil

NCT05382806

Flumazenil Adverse Reaction Ambulatory Surgery Postoperative Nausea +1 more

COMPLETED NA

Effect of Combined Administration of Sevoflurane and Remimazolam on Emergence

NCT06385002

Gynecological Surgery

COMPLETED NA

Remimazolam and Remifentanil Without Neuromuscular Blocking Agent

NCT05025410

Myoma;Uterus Polyp Endometrium Unspecified Condition Associated With Female Genital Organs and Menstrual Cycle

COMPLETED

Effects of Flumazenil on Recovery After Total Intravenous Anesthesia With Remimazolam

NCT05939674

Flumazenil Adverse Reaction Remimazolam Hip Joint +1 more

RECRUITING NA

Comparison of Remimazolam and Midazolam for Preventing Intraoperative Nausea and Vomiting During Cesarean Section Under Spinal Anesthesia

NCT05736341

Pregnancy Cesarean Section Spinal Anesthesia

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

To date, there has not been a study investigating the impact of remimazolam on quality of recovery (QoR). This study evaluates the effect of remimazolam on QoR of participants undergoing general anesthesia using remimazolam-remifentanil total intravenous anesthesia (TIVA) for hysteroscopy as day surgery basis. Herein, the investigators used the translated Korean version of the 15-item Quality of Recovery-15 (QoR-15K) questionnaire, which was previously validated in Korean surgical participants.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Day Surgery Patient Outcome Assessment Quality of Recovery Remimazolam

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Remimazolam

Effects of remimazolam on quality of recovery scores after ambulatory hysteroscopic surgery

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

the translated Korean version of 15-item Quality of Recovery scale (QoR-15K)

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult woman scheduled for ambulatory gynecological surgery under general anesthesia
* American Society of Anesthesiology grade 1 or 2

Exclusion Criteria

* Underlying diseases: liver, kidney, brain nervous system, glaucoma
* Patients with BMI greater than 30 and less than 18.5
* Patients diagnosed with sleep apnea
* Alcohol or drug dependent patients
* Patients with severe or acute respiratory failure
* Lactose intolerance
* Dextran 40 hypersensitivity
* Patients in shock or coma

Minimum Eligible Age

19 Years

Maximum Eligible Age

75 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No